In partnership with bioMérieux, InDevR’s Erica Dawson, Ph.D., is presenting how the multiplex immunoassay platform, VaxArray, empowers Critical Quality Attribute (CQA) testing for multivalent mRNA vaccines.
Analytical methods capable of rapidly and simultaneously assessing all components in multivalent vaccines become increasingly important with the introduction of high-valency vaccines and rapid manufacturing platforms, particularly for nucleic acid-based vaccines. This presentation will focus on key applications of the microarray-based, multiplexed VaxArray platform in vaccine analytics, with a focus on how the technology can be effectively utilized throughout the development and clinical validation of multivalent mRNA vaccines. Using influenza mRNA vaccines as a case study, we present data from a variety of on-market and in-development VaxArray assays to highlight how the platform empowers cost-effective analytical development throughout the mRNA vaccine product lifecycle.
Key learning points
- Learn why analytical methods developed for traditional monovalent vaccines (ELISA, SRID, & others) are a bottleneck for mRNA vaccine development and manufacturing
- Understand how InDevR utilizes decades of multiplexed assay development and manufacturing experience to accelerate mRNA vaccine development
- Learn more about the ways InDevR continuously monitors and verifies assay kit performance for new strains semi-annually
- Understand how InDevR’s expert services team can develop custom off-the-shelf assays specific to your vaccine samples
- Ask InDevR Chief R&D Officer questions about analytical development challenges during the vaccine lifecycle.
